Study of IMC-A12, Alone or in Combination With Cetuximab, in Participants With Recurrent or Metastatic Squamous Cell Carcinoma (MSCC) of the Head and Neck
Public ClinicalTrials.gov record NCT00617734. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Phase 2 Open-Label Study of IMC-A12, as a Single Agent or in Combination With Cetuximab, in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck and Disease Progression on Prior Platinum-Based Chemotherapy
Study identification
- NCT ID
- NCT00617734
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Eli Lilly and Company
- Industry
- Enrollment
- 97 participants
Conditions and interventions
Conditions
Interventions
- IMC-A12 (cixutumumab) Biological
- cetuximab (Erbitux ®) Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 29, 2008
- Primary completion
- Jan 31, 2012
- Completion
- Jun 30, 2012
- Last update posted
- Apr 16, 2018
2008 – 2012
United States locations
- U.S. sites
- 14
- U.S. states
- 12
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| ImClone Investigational Site | Orange | California | 92868 | — |
| ImClone Investigational Site | Miami | Florida | 33136 | — |
| ImClone Investigational Site | Orlando | Florida | 32806 | — |
| ImClone Investigational Site | Atlanta | Georgia | 30322 | — |
| ImClone Investigational Site | Chicago | Illinois | 60637 | — |
| ImClone Investigational Site | Baltimore | Maryland | 21231 | — |
| ImClone Investigational Site | Boston | Massachusetts | 02115 | — |
| ImClone Investigational Site | Rochester | Minnesota | 55905 | — |
| ImClone Investigational Site | New York | New York | 10003 | — |
| ImClone Investigational Site | The Bronx | New York | 10467 | — |
| ImClone Investigational Site | Pittsburgh | Pennsylvania | 15232 | — |
| ImClone Investigational Site | Nashville | Tennessee | 37232 | — |
| ImClone Investigational Site | Houston | Texas | 77030 | — |
| ImClone Investigational Site | Charlottesville | Virginia | 22908 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00617734, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 16, 2018 · Synced May 14, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00617734 live on ClinicalTrials.gov.